Sign Up Today and Learn More About Geneos Therapeutics Stock
Invest in or calculate the value of your shares in Geneos Therapeutics or other pre-IPO companies through EquityZen's platform.
Geneos Therapeutics Stock (GEET)
Geneos Therapeutics is a developer of a neo-antigen based personalized immunotherapy designed to offer cancer treatment.
About Geneos Therapeutics Stock
Founded
2016
Headquarters
Plymouth Meeting, PA, US
Industries
Science and Engineering, Health Care, Biotechnology
Geneos Therapeutics Press Mentions
Stay in the know about the latest news on Geneos Therapeutics
Vaccines and methods of using the same to treat wnt-related cancer
patents • Feb 09, 2025
Individualized cancer epitopes and methods of using the same
patents • Feb 09, 2025
Geneos' Vaccine Outperforms Liver Cancer Immunotherapies
genengnews • Jul 04, 2024
Geneos cancer vaccine shrinks liver tumors in small trial
reuters • Jul 04, 2024
Promising Personalized Approach to Liver Cancer Therapy Made Possible by DNA-based Neoantigen Research ...
globenewswire • Jun 05, 2024
Geneos Therapeutics Management
Leadership team at Geneos Therapeutics
Founder, President & CEO, Director
Niranjan Y. Sardesai
Vice President, Head of Operations and Business Development
James A. Barlow
Join now and verify your accreditation status to gain access to:
- Geneos Therapeutics Current Valuation
- Geneos Therapeutics Stock Price
- Geneos Therapeutics Management
- Available deals in Geneos Therapeutics and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Geneos Therapeutics Cap Table and Funding History by Share Class and Liquidity Preferences
- Geneos Therapeutics Revenue and Financials
- Geneos Therapeutics Highlights
- Geneos Therapeutics Business Model
- Geneos Therapeutics Risk Factors
- Geneos Therapeutics Research Report from SACRA Research
Trading Geneos Therapeutics Stock
How to invest in Geneos Therapeutics stock?
Accredited investors can buy pre-IPO stock in companies like Geneos Therapeutics through EquityZen funds. These investments are made available by existing Geneos Therapeutics shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Geneos Therapeutics stock?
Shareholders can sell their Geneos Therapeutics stock through EquityZen's private company marketplace. EquityZen's network includes over 360K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
